Peter Feinberg Acquires 5,000 Shares of Immuneering (NASDAQ:IMRX) Stock

Key Points

• Peter Feinberg, a director at Immuneering, purchased 5,000 shares at an average price of $7.18, increasing his total holdings to 141,766 shares valued at approximately $1,017,879.88.
• Immuneering's stock closed at $6.53, demonstrating a drop of $0.22, with a 52-week range of $1.10 to $10.08 and a market capitalization of $271.45 million.
• Multiple analysts have issued positive ratings and increased price targets for Immuneering, with Oppenheimer projecting a target of $30.00 per share, indicating strong growth potential.

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) Director Peter Feinberg bought 5,000 shares of the stock in a transaction dated Monday, September 29th. The shares were bought at an average cost of $7.18 per share, with a total value of $35,900.00. Following the completion of the purchase, the director directly owned 141,766 shares of the company's stock, valued at approximately $1,017,879.88. This trade represents a 3.66% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Immuneering Price Performance

Shares of NASDAQ:IMRX traded down $0.22 during trading hours on Tuesday, hitting $6.53. The company's stock had a trading volume of 1,498,735 shares, compared to its average volume of 1,423,648. The firm's fifty day moving average price is $5.48 and its 200 day moving average price is $3.27. Immuneering Corporation has a 52 week low of $1.10 and a 52 week high of $10.08. The company has a market capitalization of $271.45 million, a price-to-earnings ratio of -3.46 and a beta of 0.43.

Immuneering (NASDAQ:IMRX - Get Free Report) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.40) EPS for the quarter, hitting analysts' consensus estimates of ($0.40). On average, equities research analysts predict that Immuneering Corporation will post -1.86 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IMRX has been the topic of several analyst reports. Oppenheimer lifted their price target on shares of Immuneering from $21.00 to $30.00 and gave the stock an "outperform" rating in a report on Thursday, September 25th. Chardan Capital upped their price target on shares of Immuneering from $13.00 to $20.00 and gave the company a "buy" rating in a research note on Friday. HC Wainwright reissued a "buy" rating and set a $11.00 price objective on shares of Immuneering in a report on Tuesday. Needham & Company LLC upped their target price on Immuneering from $8.00 to $11.00 and gave the company a "buy" rating in a research report on Monday, September 15th. Finally, Mizuho boosted their price target on Immuneering from $8.00 to $10.00 and gave the company an "outperform" rating in a research note on Wednesday, June 18th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $16.40.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its holdings in Immuneering by 2.0% in the 2nd quarter. Geode Capital Management LLC now owns 230,275 shares of the company's stock worth $776,000 after buying an additional 4,458 shares during the last quarter. Two Sigma Investments LP boosted its stake in Immuneering by 25.0% during the 4th quarter. Two Sigma Investments LP now owns 50,557 shares of the company's stock worth $111,000 after purchasing an additional 10,126 shares during the last quarter. HighTower Advisors LLC grew its holdings in shares of Immuneering by 17.7% during the first quarter. HighTower Advisors LLC now owns 83,960 shares of the company's stock worth $128,000 after buying an additional 12,600 shares in the last quarter. Kingsview Wealth Management LLC acquired a new stake in shares of Immuneering in the second quarter valued at about $47,000. Finally, Jane Street Group LLC purchased a new position in shares of Immuneering in the first quarter worth about $32,000. 67.65% of the stock is currently owned by hedge funds and other institutional investors.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.